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Axonin-1/TAG-1 mediates cell-cell adhesion by a cis-assisted
trans-interaction
Abstract
The neural cell adhesion molecule axonin-1/TAG-1 mediates cell-cell interactions via homophilic and
heterophilic contacts. It consists of six Ig and four fibronectin type III domains anchored to the
membrane by glycosylphosphatidylinositol. The recently solved crystal structure indicates a module
composed of the four N-terminal Ig domains as the contact site between trans-interacting axonin-1
molecules from apposed membranes. Here, we have tested domain-specific monoclonal antibodies for
their capacity to interfere with homophilic binding in a cell aggregation assay. The results confirmed the
existence of a binding region within the N-terminal Ig domains and identified a second region
contributing to homophilic binding on the third and fourth fibronectin domains near the C terminus. The
perturbation of each region alone resulted in a complete loss of cell aggregation, suggesting that
axonin-1-mediated cell-cell contact results from a cooperative action of two homophilic binding regions.
The data support that axonin-1-mediated cell-cell contact is formed by cis-assisted trans-binding. The
N-terminal binding regions of axonin-1 establish a linear zipper-like string of trans-interacting axonin-1
molecules alternately provided by the two apposed membranes. The C-terminal binding regions
strengthen the cell-cell contact by enhancing the expansion of the linear string into a two-dimensional
array via cis-interactions. Cis-assisted trans-binding may be a basic binding mechanism common to
many cell adhesion molecules.
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The neural cell adhesion molecule axonin-1/TAG-1 me-
diates cell-cell interactions via homophilic and hetero-
philic contacts. It consists of six Ig and four fibronectin
type III domains anchored to the membrane by glyco-
sylphosphatidylinositol. The recently solved crystal
structure indicates a module composed of the four
N-terminal Ig domains as the contact site between
trans-interacting axonin-1 molecules from apposed
membranes. Here, we have tested domain-specific
monoclonal antibodies for their capacity to interfere
with homophilic binding in a cell aggregation assay. The
results confirmed the existence of a binding region
within the N-terminal Ig domains and identified a sec-
ond region contributing to homophilic binding on the
third and fourth fibronectin domains near the C termi-
nus. The perturbation of each region alone resulted in a
complete loss of cell aggregation, suggesting that axo-
nin-1-mediated cell-cell contact results from a coopera-
tive action of two homophilic binding regions. The data
support that axonin-1-mediated cell-cell contact is
formed by cis-assisted trans-binding. The N-terminal
binding regions of axonin-1 establish a linear zipper-like
string of trans-interacting axonin-1 molecules alter-
nately provided by the two apposed membranes. The
C-terminal binding regions strengthen the cell-cell con-
tact by enhancing the expansion of the linear string into
a two-dimensional array via cis-interactions. Cis-as-
sisted trans-binding may be a basic binding mechanism
common to many cell adhesion molecules.
Interactions between cell adhesion molecules on the surface
of neural cells play a key role in several stages of neural
development, including cell migration, axon growth and guid-
ance, establishment of synaptic connections, and myeliniza-
tion. A well characterized representative of a neural cell adhe-
sion molecule is axonin-1 (1), the avian homolog of TAG-1 (2).
Axonin-1 is a member of the immunoglobulin superfamily. It
consists of six Ig and four fibronectin type III (Fn)1 domains
and is anchored to the cell membrane by a glycosylphosphati-
dylinositol anchor. Axonin-1 has been found to engage in dif-
ferent interactions with other cell-surface or extracellular ma-
trix components. Axonin-1 on one cell binds homophilically to
axonin-1 on another cell (3). Heterophilic interactions of axo-
nin-1 have been reported with the cell adhesion molecules
NgCAM (4), NrCAM (5), and NCAM (6); the proteoglycans
neurocan and phosphacan; and the extracellular matrix com-
ponent tenascin C (6).
As a first step toward a detailed molecular description of the
homophilic and heterophilic interactions of axonin-1, we have
determined the crystal structure of the first four N-terminal
domains of axonin-1 (7). We found a U-shaped arrangement of
the Ig domains, resulting in the formation of a compact module.
In the crystals, these modules are aligned in a string. Adjacent
modules exhibit a large edge-to-face contact and are oriented in
an antiparallel fashion, with their C termini pointing perpen-
dicularly to the string. This arrangement suggests that cell
adhesion by homophilic axonin-1 interactions occurs by the
formation of a linear zipper-like array in which the axonin-1
molecules are alternately provided by the two apposed mem-
branes (Fig. 1). In confirmation of this model, mutations in a
loop critical for the formation of the zipper result in the loss of
the homophilic binding capacity of axonin-1 (7).
Here, we provide evidence that monoclonal antibodies binding
either to the first Ig domain or to the third and fourth Fn domains
perturb the formation of aggregates between axonin-1-express-
ing myeloma cells. Our results indicate that two distinct binding
sites, one at the N terminus and one at the C terminus of axo-
nin-1, are involved in axonin-1-mediated cell-cell contact. Per-
turbing the binding in each region alone resulted in a complete
loss of axonin-1-mediated cell-cell contact. Therefore, we propose
a model for axonin-1-mediated cell-cell binding based on a coop-
erative action of the N- and C-terminal binding sites.
EXPERIMENTAL PROCEDURES
Monoclonal Antibodies—Axonin-1 was purified from the ocular vit-
reous fluid of embryonic day 14 chicken embryos as described previ-
ously (8). For the production of monoclonal antibodies, four 6-week-old
BALB/c mice were immunized by subcutaneous injection of 20 or 25 g
of axonin-1 in complete Freund’s adjuvant, followed by three to four
booster injections of 10–20 g of axonin-1 in incomplete Freund’s ad-
juvant. 3.5 days before spleens were removed, the mice received a last
booster injection of 15 g of axonin-1 in phosphate-buffered saline.
One-half was injected into the tail vein, and the other half into the
peritoneum. Monoclonal antibodies were produced according to the
protocol given by Fazekas de St. Groth and Scheidegger (9). For fusion
with spleen cells, the myeloma cell line X63-Ag8.653 was used. All
clones resulting from a fusion were tested 11 days after the fusion, and
the test was repeated for slowly growing and negative clones at days 13,
16, and 19. Supernatants were tested for their capacity to recognize
native purified axonin-1 in a dot immunobinding assay on nitrocellu-
lose. Binding mAbs were visualized with peroxidase-conjugated anti-
mouse IgG antibody (Kirkegaard & Perry Laboratories). Positive clones
were subcloned at least three times.
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Perturbation of Myeloma Cell Aggregation by Anti-axonin-1
mAbs—To test anti-axonin-1 mAbs for the capacity to interfere with the
formation of cell aggregates, the axonin-1-expressing myeloma cell line
5u (3) was expanded to an approximate density of 105 cells/ml, centri-
fuged, and resuspended in fresh medium to a final cell number of 106
cells/ml. For testing aggregation, an aliquot of 50 l was transferred to
each well of a microtiter plate (5  104 cells/well). Monoclonal IgG or
Fab were added to a final concentration of 50 g/ml. Polyclonal IgG or
Fab were used at 1 mg/ml. To test for aggregation, the cells were
incubated at 4 °C for 45 min as described previously (3). Thereafter, cell
aggregation was assessed by counting single cells, small aggregates of
5–10 cells, and large aggregates of 10 cells on an inverted phase-
contrast microscope. For each measurement, 100 observations were
collected and classified into the three groups (single cells, small aggre-
gates of 5–10 cells, and large aggregates of 10 cells). For each condi-
tion, the percentage of observations within each category was deter-
mined as the ratio between the experimental condition and the control
with no antibody added. To test for statistical significance, we used
Student’s t test.
Domain Deletion Mutants and Hybrids of Axonin-1—Deletion mut-
ants and hybrids of axonin-1 were constructed by loop-out oligonucleo-
tide-directed mutagenesis and stably transfected into myeloma cells as
described previously (10). The axonin-1 mutants were named according
to the domain that was deleted. For example, in Ig2, the second Ig
domain of axonin-1 was excised. The domain deletion mutants used in
this study and the corresponding peptide fragments that were excised
are listed below, giving the first and last amino acids of the excised
peptide fragment in reference to the amino acid sequence position of
wild-type axonin-1 (1): 2*1  (Phe126–Glu227) with the second Ig
domain replaced by an additional first Ig domain, Ig2  (Phe126–G-
lu227), Ig3  (Asp228–His319), Ig5  (Leu410–Arg501), Ig6  (A-
sp502–Ser594), Fn2  (Thr706–Pro807), Fn3  (Lys808–Pro908),
Fn4 (Pro907–Gly1001), Ig12 (Met27–Phe124/Ser131–Ala229), Ig-
1234  (Met27–Phe124/Ser131–Leu410), and Ig1234  (Ala409–
Ala992)/V994F.
The hybrids between axonin-1 and the related cell adhesion molecule
F11 (contactin) were previously described by Lierheimer et al. (11). The
axonin-1/F11 hybrid consisted of Met1–Leu693 of axonin-1 and Pro686–
Phe1009 of F11. The F11/axonin-1 hybrid was composed of Met1–Pro686
of F11 and Ser695–Leu1036 of axonin-1.
Transfection of Myeloma Cells—Stably transfected myeloma cells
(J558L) were obtained by protoplast fusion (12) with the constructs
specified above. To obtain independent transfectants, the cells were
diluted in Dulbecco’s modified Eagle’s medium containing 10% fetal calf
serum and cultivated in microtiter plates at 37 °C in 10% CO2. After 2
days, transfected clones were selected by addition of 5 mM L-histidinol
(Sigma, Buchs, Switzerland). Transfection efficiencies were 104. Af-
ter 10 days, the cells were screened for recombinant expression by
immunofluorescence staining using rabbit antiserum against axonin-1
or F11 (1:500 dilution) and fluorescein isothiocyanate (FITC)-conju-
gated goat anti-rabbit IgG antibody (1:100 dilution; Zymed Laborato-
ries Inc., South San Francisco, CA). Colonies with high level expression
were subcloned. Expression of domain deletion mutants was tested by
Western blot analysis. Cell-surface exposition of the expressed domain
deletion mutants was visualized by indirect immunofluorescence using
goat anti-axonin-1 serum and FITC-conjugated rabbit anti-goat IgG
antibody (Zymed Laboratories Inc.).
Epitope Mapping of mAbs with Axonin-1 Domain Deletion Mutants
Expressed by J558L Cells—To test binding of mAbs, the J558L my-
eloma cells expressing wild-type or mutant axonin-1 were preincubated
for 2 h at 37 °C with hybridoma supernatant or monoclonal anti-IgG
antibody at a concentration of 10 g/ml in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum. The cells that had bound the
antibodies were detected by incubation with FITC-conjugated goat anti-
mouse IgG antibody (1:200 dilution; Cappel Organon Teknika nv, Turn-
hout, Belgium). The preparation was examined with a Leitz DMR
fluorescence microscope (Leica AG, Glattbrugg, Switzerland) and ana-
lyzed with an automated microplate fluorescence reader (Cytofluor
2000, Millipore). Expression of mutant axonin-1 was confirmed using
goat polyclonal anti-axonin-1 antibody at a concentration of 500 g/ml
and FITC-conjugated rabbit anti-goat IgG antibody at a dilution of
1:100.
Microscopy—Clustering of axonin-1 molecules was recorded by a
Zeiss laser scanning microscope (Axioplan LSM 310) using identical
conditions for all images. Contrast was set to 418, and brightness to
9999.
Adenoviral Expression in CV-1 Cells—An adenovirus vector contain-
ing an expression cassette for the deletion mutant Ig5, termed
AdAxIg5, was constructed as previously reported for the adenovirus
vector coding for the full-length axonin-1 sequence (AdAx) (13). In both
constructs, expression of the transgene is controlled by the cytomega-
lovirus promoter. For viral infection, CV-1 cells were cultured in 60-mm
culture dishes until they reached 30% confluency. The cells were then
trypsinized, counted, and allowed to settle down in culture medium.
adenovirus (multiplicity of infection  20) was added; and 3 h later, the
medium was replaced with new culture medium. The experiments were
started 48 h after transfection.
Quantification of Immunostaining in Axonin-1-expressing CV-1
Cells—To quantify the accumulation of axonin-1 and Ig5 at the cell
contact area of two expressing cells, we determined the distribution
coefficient (q) using a laser scanning microscope and NIH Image soft-
ware. q was equal to the ratio between the fluorescence intensity in the
contact area of the two cells (Ica) per area (a) and the average of the
fluorescence intensity of the two cell surfaces (Ics1 and Ics2, respectively)
per area: q  (Ica/a)/(((Ics1  Ics2)*1⁄2)/a).
RESULTS
Perturbation Studies Identify Monoclonal Antibodies That
Inhibit Axonin-1-mediated Cell-Cell Aggregates—To localize
the surface areas of axonin-1 that are involved in homophilic
FIG. 1. Zipper model for axonin-1-mediated cell-cell adhesion
as deduced from the crystal structure of the first four Ig do-
mains of axonin-1. The crystal structure reveals that the first four Ig
domains of axonin-1 are arranged in a U-shape and form a compact
module (7). The contacts of the axonin-1 molecules in the crystals
prompted a zipper model for axonin-1-mediated cell-cell adhesion in
which trans-interacting axonin-1 molecules are alternately provided by
the two apposed membranes. With an extended structure of the trans-
bound axonin-1 molecules, apposed membranes would assume a maxi-
mum distance of 58 nm. For clarity, axonin-1 molecules of the upper
and lower membrane are shown in distinct colors. Ig domains are green
(upper membrane) or red (lower membrane), and Fn domains are tur-
quoise (upper membrane) or orange (lower membrane).
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binding, we tested the capacity of monoclonal antibodies to
perturb axonin-1-mediated cell-cell binding and mapped their
epitopes on the surface of native axonin-1. To identify such
antibodies, we used a cell aggregation assay with myeloma
cells stably expressing wild-type axonin-1. The axonin-1-ex-
pressing myeloma cells form large cell aggregates mediated by
homophilic interactions between axonin-1 molecules (3). We
tested 27 mAbs for their capacity to interfere with axonin-1-
dependent myeloma cell aggregation. In a pilot experiment,
purified mAbs were tested in their IgG form. We found seven
mAbs that clearly prevented the formation of aggregates. To-
gether with a random selection of non-perturbing mAbs, these
aggregation-perturbing mAbs were subsequently tested as Fab
for their capacity to dissociate axonin-1-expressing myeloma
cell aggregates (Fig. 2). All seven aggregation-perturbing mAbs
reduced the percentage of aggregates composed of 10 cells to
10% or less (Fig. 2i). Smaller aggregates composed of at least
five cells were still observed, but their number was45% of the
control values. The most potent inhibitors of homophilic bind-
ing (U77F8, V10C7, and X9C3) perturbed myeloma cell aggre-
gation completely. In the presence of these mAbs, as with
polyclonal anti-axonin-1 Fab antibodies, virtually no cell aggre-
gates were formed. Indirect immunofluorescence staining was
used to show that the mAbs that had no effect on the formation
of myeloma cell aggregates were capable of binding to cell-
surface exposed axonin-1, indicating that their inability to per-
turb axonin-1-mediated cell aggregation was not due to an
inaccessibility of their corresponding epitopes in the mem-
brane-bound form of axonin-1.
Anti-axonin-1 Antibodies Perturbing Cell-Cell Aggregation
Are Directed against Two Distinct Regions: Either the N or C
Terminus—To localize the epitopes of the mAbs, we used do-
main deletion mutants of axonin-1 and axonin-1/F11 chimeras
stably expressed on the surface of J558L myeloma cells. Entire
domains of axonin-1, as defined by their homology to the Ig
variable domains or the fibronectin type III domains (1) and by
exon/intron borders of the axonin-1 gene (14), were deleted by
oligonucleotide-directed mutagenesis. Mutant forms of axo-
nin-1 were cloned into the axonin-1 expression vector pMAX
(3). Vectors carrying these constructs were introduced into
myeloma cells by protoplast fusion (12). Immunocytochemical
staining revealed that all mutants, except Ig1, were ex-
pressed on the surface of J558L cells. No axonin-1 immunore-
activity was detectable on parental myeloma cells. Myeloma
cells stably expressing axonin-1 and axonin-1 deletion mutants
on their surface were used for epitope mapping. The presence of
an epitope recognized by a particular mAb was assessed by
indirect immunofluorescence staining using FITC-conjugated
anti-mouse IgG antibody and fluorescence measurement in the
Cytofluor 2000 automated microplate fluorescence reader.
Based on the absence of binding to myeloma cells expressing a
particular deletion mutant, the epitope of a mAb was allocated
to a specific domain of axonin-1 (Fig. 3). In our series of 27
mAbs, three were mapped to Ig domain 1 (Ig1), one to Ig3, four
to Ig4, one to Ig5, one to Ig6, one to Fn domain 1 (Fn1), one to
Fn2, two to Fn3, and five to Fn4. Five mAbs failed to bind to
mutants lacking one of the first three Ig domains. Of these five
mAbs, four were also unable to bind to mutants lacking the
fourth Ig domain (10). Three mAbs did not bind to mutants
lacking either the third or fourth Fn domain.
Three of the seven mAbs that interfered with myeloma cell
aggregation (U77F8, X7F6, and V3B3) had their cognate
epitopes on the first Ig domain. The other four mAbs (X9E9,
X9F6, V10C7, and X9C3) were directed to epitopes located on
the two C-terminal Fn domains. The epitopes of V10C7 and
X9C3 were unequivocally on Fn4, whereas the antibodies of
X9E9 and X9F6 required the presence of both Fn3 and Fn4 for
binding. The epitopes of the 20 axonin-1-binding antibodies
that did not affect axonin-1-mediated myeloma cell aggregation
were distributed over the entire axonin-1 molecule. In partic-
ular, we found non-perturbing antibodies with epitopes on the
same domains as the epitopes of the aggregation-perturbing
antibodies, i.e. on the Ig1234 domain conglomerate and on the
third and fourth Fn domains. One of the Ig1234-binding inef-
FIG. 2. Antibody perturbation of
the aggregation of axonin-1-express-
ing myeloma cells. a– h, phase-con-
trast images of axonin-1-expressing my-
eloma cells under selected conditions.
Axonin-1-expressing myeloma cells
formed aggregates (a). Cell aggregation
was not perturbed by non-binding anti-
body 187.1 (b) and anti-axonin-1 mAb
X9H8 (c). Polyclonal anti-axonin IgG an-
tibody prevented cell aggregation (d).
Anti-axonin-1 mAbs U77F8 (e), V3B3 (f),
X9C3 (g), and X9E9 (h) prevented cell
aggregation. Bar  50 m. i, quantifica-
tion of myeloma cell aggregation. Axo-
nin-1-expressing myeloma cells were in-
cubated with 50 g/ml monoclonal anti-
axonin-1 Fab antibodies or 1 mg/ml
polyclonal anti-IgG antibodies. The per-
centage of cell aggregates containing 4
cells and 10 cells, respectively, was de-
termined by counting aggregates and
forming the ratio to the aggregates in
the negative control (no antibody (Ab)).
Two classes are presented: aggregates
containing 4 cells and aggregates
containing 10 cells. Error bars indicate
the S.E. (n  3). With mAbs V10C7 and
X9C3 and with polyclonal goat anti-
axonin-1 antibodies (GAx-1), no aggre-
gates with 10 cells were found. With
mAb U77F8, we found no aggregates at
all.
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fective antibodies (X9H8) had previously been found to perturb
the heterophilic binding of axonin-1 and NgCAM (10). To-
gether, these results indicate that the mAbs that interfere with
the homophilic trans-binding of axonin-1 are directed against
epitopes that are clustered in two distinctive areas of the axo-
nin-1 molecule, one at the N terminus and the other at the C
terminus.
An Extended Domain Arrangement Facilitates the Redistri-
bution of Axonin-1 to the Cell-Cell Contact Area—Monomeric
axonin-1 has been found to exhibit a horseshoe-like domain
arrangement in which the N-terminal domain conglomerate of
the first four Ig domains comes into close proximity with the
C-terminal Fn domains (10). In this conformation, the binding
site for NgCAM is only accessible for cis (but not trans)-inter-
action (15). Shortening axonin-1 by deleting the fifth or sixth Ig
domain enables trans-binding of NgCAM (10). Because back-
bending of the N-terminal Ig domains onto the C-terminal Fn
domains is less likely in the shortened axonin-1 molecules, the
enhanced NgCAM-binding axonin-1 mutant was explained by a
statistical shift toward the extended form, in which the Ng-
CAM-binding N-terminal Ig domains are better accessible for a
trans-interaction. Likewise, an extended structure has been
postulated for axonin-1 engaged in homophilic trans-binding
(7). These observations raised speculations that the cis-binding
site in the Fn region was masked in the back-folded form, but
became accessible in the extended form of axonin-1.
To test whether the propensity of axonin-1 to associate with
the cell-cell contact area was enhanced by an extended struc-
ture of axonin-1 as compared with the horseshoe-like structure,
we analyzed the cell-cell contact regions in confluent cultures of
CV-1 cells expressing different forms of axonin-1. We chose
axonin-1 in which the fifth Ig domain was deleted (10) as a form
of axonin-1 with a presumptive extended structure. The CV-1
cells were infected with a recombinant adenovirus containing
an expression cassette of either wild-type axonin-1 (AdAx) or
the Ig5 mutant (AdAxIg5). 2 days after viral infection, the
cells were stained for surface axonin-1 by indirect immunoflu-
orescence (Fig. 4). As demonstrated in Fig. 4a, the cell contact
zones between axonin-1-expressing cells showed no or at best
weak accumulation of axonin-1 immunoreactivity. In contrast,
cells expressing the Ig5 mutant of axonin-1 exhibited a pro-
nounced accumulation of axonin-1 immunoreactivity along the
contact sites with other cells expressing the axonin-1 mutant
(Fig. 4b). Measurements of the fluorescence intensities over
free cell-surface membranes and over cell contact lines con-
firmed a significant accumulation of mutant axonin-1 com-
pared with wild-type axonin-1 at cell contact lines (Fig. 4c).
These results indicate an enhanced propensity of the extended
form of axonin-1 to associate with areas of cell-cell contact.
DISCUSSION
Cis-assisted Trans-binding: A Model for Axonin-1-mediated
Cell-Cell Adhesion—We found that the epitopes of function-
blocking monoclonal antibodies against axonin-1 were located
in two distant regions, one close to the N terminus (Ig1) and the
other close to the C terminus (Fn3 and Fn4). Perturbing the
binding of each region alone resulted in a complete loss of
axonin-1-mediated cell-cell adhesion. Theoretically, homophilic
axonin-1 binding involving two distant binding sites could be
formed by (a) an interaction of the N-terminal site of axonin-1A
(NA) with the C-terminal site of axonin-1B (CB) (and NB with
CA), (b) two distinct trans-interactions between axonin-1A and
axonin-1B (NA-NB and CA-CB), or (c) a cooperation of a trans-
interaction between the N termini (NA-NB) and a cis-interac-
tion between the C termini of the trans-interacting axonin-1
molecules with the C termini of adjacent axonin-1 molecules
FIG. 3. Epitope mapping of mono-
clonal anti-axonin-1 antibodies. a, do-
main structure of axonin-1, hybrids com-
posed of axonin-1 and F11, and axonin-1
deletion mutants used for epitope map-
ping. The Ig and Fn domains of axonin-1
are represented as red and orange ellip-
soids, respectively; the corresponding do-
mains of F11 are indicated in dark blue
and light blue, respectively. The axonin-
1/F11 hybrid (Ax-F11) is composed of all
Ig domains and the first Fn domain of
axonin-1 and the last three Fn domains of
F11; the complementary hybrid F11/axo-
nin-1 (F11-Ax) is composed of all Ig do-
main and the first Fn domain of F11 and
the last three Fn domains of axonin-1.
Deleted domains are indicated by lines,
and the deleted domain(s) are indicated
on the left. b, profiles of the binding of 27
mAbs raised against native axonin-1 to
axonin-1/F11 hybrids and deletion mu-
tants of axonin-1 (Ax-1). The hybrids and
deletion mutants were expressed on the
surface of myeloma cells, and binding was
analyzed by indirect immunofluorescence
using an automated microplate fluores-
cence reader. , binding; , no binding.
No sign indicates “not tested.” The second
line from the bottom indicates the do-
main(s) bearing the epitope. The last line
indicates whether the antibody perturbed
the aggregation of myeloma cells express-
ing wild-type axonin-1. The colored areas
indicate the aggregation-perturbing
mAbs.
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(CA-CA	 and CB-CB	). The reverse of the interactions of possi-
bility c is also possible (CA-CB with NA-NA	 and NB-NB	), al-
though, based on steric reasons, less likely.
The finding that mAbs against either region alone are capa-
ble of abolishing axonin-1-mediated cell-cell contacts is obvious
for possibilities a and c. For possibility b, the explanation would
be that only N-N or C-C trans-interactions would not be suffi-
cient to support cell-cell binding.
Alternatively, for possibility d, one could speculate that the
binding of mAbs to the membrane-proximal epitopes of axo-
nin-1 might perturb a role of the Fn region in controlling the
conformation or dynamic accessibility of the Ig1–4 region. This
possibility is plausibly supported by the observation that mo-
nomeric axonin-1 has a horseshoe form that is thought to be
stabilized by an intramolecular contact between the N-termi-
nal Ig region and the C-terminal Fn region (10).
From these possibilities, we favor a cooperation of two inter-
actions, one among N-terminal binding sites and another
among C-terminal binding sites of adjacent axonin-1 molecules
anchored to the same membrane because previous studies have
clearly demonstrated that both isolated N- and C-terminal
fragments exhibit the capacity of self-binding (7, 16). In the
crystals of the module formed by the first four Ig domains of
axonin-1, Freigang et al. (7) have identified an extended edge-
to-face contact between adjacent molecules, consistent with the
formation of a linear string of molecules. Adjacent molecules in
the string are in antiparallel orientation, and their C termini
point perpendicularly to the axis of the string. This arrange-
ment prompted a model for axonin-1-mediated cell-cell adhe-
sion in which the N-terminal Ig1–4 modules of axonin-1 mol-
ecules of apposed membranes become engaged in a homophilic
trans-contact by interlacing in a zipper-like manner. In support
of the model, the mutation of two amino acids located within
the edge-to-face contact region (H186A and F189A) resulted in
a complete loss of axonin-1-mediated cell aggregation. Like-
wise, Tsiotra et al. (16) have reported an aggregation of Schnei-
der line 2 cells transfected with the Fn moiety of TAX-1, the
human ortholog of axonin-1. These results unequivocally re-
flect the existence of a homophilic binding site within the Fn
moiety. However, although the evidence for this binding site
has been obtained in an assay reporting for trans-interactions,
it is possible that the biologically relevant in vivo interaction
reflected in this assay occurs in cis. As previously observed
with axonin-1 and NgCAM, topological information may be lost
in binding assays due to orientation, conformational, or sterical
deviations from the normal situation (for a well documented
example, compare Refs. 4 and 15). In the case of truncated
TAX-1 molecules overexpressed on the surface of Schneider
cells, a cis-binding site between Fn segments arranged in par-
allel (as expected for a cis-interaction) could readily cause
cell-cell aggregation via trans-binding if enough orientation
freedom is provided to allow a tilt of the binding segment from
the perpendicular to the membrane plane. Because of their
proximity to the membrane, these binding sites in the Fn
region are more likely to interact in cis than in trans. Distance
measurements between a silicon substratum coated with co-
valently coupled full-length axonin-1 and growth cones of cul-
tivated sensory ganglial neurons (17) indeed revealed values
that exclude a trans-interaction between the Fn regions (see
below for quantitative aspects). Therefore, we propose that the
binding site in the Fn region mediates cis-contacts between
the membrane-proximal Fn regions of axonin-1 molecules of
the same membrane.
Based on the results presented here and published observa-
tions, we propose a cis-assisted trans-binding mechanism for
the axonin-1-mediated cell-cell aggregation. As depicted in Fig.
5, the N-terminal binding site (located on a domain module
comprising Ig1–4) binds in trans, forming a linear zipper-like
array with molecules alternately provided by the two apposed
membranes (7). The binding is strengthened by the cis-contacts
of the C-terminal binding sites (located on Fn3 and Fn4), which
mediate a side-by-side arrangement of the linear strings into a
two-dimensional array. This model reconciles the currently
available observations on direct interactions between recombi-
nant fragments of axonin-1 (7, 16) and the results of our anti-
body perturbation studies on cell-cell adhesion mediated by
full-length axonin-1. The model is also in agreement with re-
cent distance measurements. Using fluorescence interference
contrast microscopy, a minimal distance of 37 nm between
growth cones of cultivated sensory ganglial neurons and a
silicon substratum coated with covalently coupled axonin-1 has
been measured (17). Based on the distance of the C termini of
adjacent axonin-1 Ig1–4 modules in the crystals (10 nm) (7),
the length of a tandem array of two Ig domains (9 nm) (7), the
length of a tandem array of two Fn domains (6 nm) (18), and
the length of the proline- and glycine-rich decapeptide between
the Ig and Fn moieties (3 nm), the membranes connected by
trans-bound axonin-1 in a completely extended conformation
would be at a maximum distance of 58 nm. Assuming that
cis-interactions between Fn domains would result in a tilt of at
least part of the domains from the perpendicular to the mem-
brane plane or that tandems of Ig and Fn domains are partially
juxtaposed, such as in CD4 (19), a considerably shorter inter-
membrane distance than that calculated for an extended struc-
ture of axonin-1 would result. Based on the measured minimal
distance of 37 nm, a homophilic trans-contact between Fn
domains (and thus, a binding model with two trans-contacts) is
excluded. With a homophilic trans-contact between the two
membrane-proximal Fn domains, membranes would be re-
FIG. 4. An extended form of axonin-1 results in enhanced ho-
mophilic binding of axonin-1 molecules at cell-cell contacts.
CV-1 cells were transfected with adenovirus bearing an expression
cassette for wild-type axonin-1 (AdAx) or axonin-1 with a deleted fifth
Ig domain (AdAxIg5). Axonin-1 missing the fifth Ig domain (AxIg5) is
thought to be in an extended form and therefore more accessible for a
receptor axonin-1 molecule on a neighbored cell. a, CV-1 cells express-
ing recombinant axonin-1 (Ax; transfected by adenovirus AdAx). b,
CV-1 cells expressing the Ig5 mutant of axonin-1 transfected by
AdAxIg5. The cells were immunostained with rabbit anti-axonin-1
antibodies. Note that in a, axonin-1 is not concentrated in the cell-cell
contact area, whereas in b, Ig5 is strongly concentrated along the
cell-cell contact area. c, quantitative analysis of the molecular distribu-
tion. A q value of 1 means that the molecular concentration in the
cell-cell contact area is the same as on the cell surface. Axonin-1 im-
munofluorescence was measured, and the ratio q between the fluores-
cence intensity per area in the cell contact zone and the cell surface was
determined. A q value 1 indicates an increased concentration in the
contact zone. CV-1 cells stably transfected with axonin-1 did not have
significantly higher axonin-1 concentrations in regions of cell-cell con-
tact. The construct with the deleted fifth Ig domain accumulated at
sites of cell-cell contact.
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quired to approach each other to 12 nm or less; with a ho-
mophilic trans-contact between the first Fn domains, an inter-
membrane distance of 24 nm or less would be required.
Establishment of an Axonin-1-mediated Cell-Cell Contact Re-
quires a Conformational Transition from the Horseshoe-like
Structure to an Extended Structure of Axonin-1—In the struc-
ture found by negative staining electron microscopy of purified
soluble axonin-1, the axonin-1 molecule is bent in a horseshoe-
like form so that its two ends become located in close proximity
(10). Thus, in the glycosylphosphatidylinositol-anchored form
of axonin-1, the four N-terminal Ig domains bearing the Ng-
CAM-binding site (20) are turned back to the cell membrane.
Based on this structure, the absence of heterophilic trans-
binding between axonin-1 and NgCAM exposed on the surface
of different myeloma cells (15) is explained. Interestingly, the
Ig5 mutant of axonin-1, in which the fifth Ig domain was
deleted, exhibits a strikingly enhanced trans-binding of Ng-
CAM (10). It is plausible for sterical reasons that the deletion of
an Ig domain in the interior of the molecule restrains the
back-folding and thus favors the extended structure in which
the N-terminal Ig1–4 module is better accessible for a trans-
binding ligand.
In this study, we have found that the Ig5 mutant of axo-
nin-1 also exhibits an enhanced tendency to associate with the
cell contact area, as demonstrated by the observation of an
increased accumulation of the Ig5 mutant at cell contact sites
in CV-1 cells (Fig. 4). As is the case of trans-binding to NgCAM,
the presumed extended structure of the Ig5 mutant may
facilitate the establishment of homophilic trans-binding by an-
ticipating the conformational transition from the horseshoe to
the extended form.
The hypothesis that a major conformational change is re-
quired for the establishment of homophilic axonin-1/axonin-1
binding is further supported by the observed discrepancy be-
tween cell-cell and Covaspheres-Covaspheres binding studies.
Axonin-1 expressed on the surface of myeloma cells in the
glycosylphosphatidylinositol-anchored form mediates cell ag-
gregation by homophilic binding (for details, see Ref. 3),
whereas no homophilic binding is observed when axonin-1 is
covalently coupled to the surface of Covaspheres via a reaction
with amino group-reactive sites on the Covaspheres. Such a
discrepancy between the function of the cell surface-anchored
form and the Covaspheres-conjugated form has not been ob-
served for NgCAM (4, 15) and NrCAM (5, 21). As a possible
explanation, one may speculate that binding to the Covas-
pheres, possibly via multiple amino groups on the surface of
each axonin-1 molecule, restricts the conformational freedom of
axonin-1 that much that it may no longer be capable of assum-
ing the extended conformation that is required for an engage-
ment in homophilic binding.
In conclusion, these results indicate that the transition from
a horseshoe to an extended form of axonin-1 is required for the
establishment of homophilic trans-binding between axonin-1
molecules of different cells. The Fn region, by binding to Ig1–4,
stabilizes the horseshoe conformation and thus reduces the
accessibility of the Ig1–4 module for trans-binding. Therefore,
the most plausible conformational consequence of a mAb bind-
ing to Fn would be an enhanced trans-interaction. Thus, both
restraining the back-bending into the horseshoe structure and
interfering with the conformational function of the Fn region
by antibodies should enhance trans-binding. The loss of cell-
cell binding in the presence of mAbs against Fn can thus not be
explained by a conformational effect. Therefore, we speculate
that the transition from the horseshoe to the extended form not
only increases the accessibility of the Ig1–4 modules for ho-
mophilic trans-binding, but in addition interferes with another
function. In view of the published homophilic binding site in Fn
(16), an interference with the side-by-side association of adja-
cent axonin-1 molecules seems to us the most plausible expla-
nation for the binding-perturbing activity of the mAbs against
Fn.
The Homophilic Cis-binding Site in the Fn Region May En-
hance the Expansion of the Cell-Cell Contact Area—A coopera-
tion of two distinctive binding sites, the one acting in cis and
the other in trans, has also been found for cell-cell interactions
mediated by cadherins (for a recent review, see Ref. 22). In
cadherins, the cis-binding site is located within the N-terminal
domain pairs, and dimerization by cis-binding has been found
to have an indispensable preparatory role for the subsequent
establishment of trans-binding. In the cis-assisted trans-bind-
ing model for axonin-1-mediated cell-cell adhesion, as proposed
here, we postulate that cis-binding is not required for the
establishment of trans-binding because, in the crystals of axo-
nin-1 Ig1–4, the linear strings of Ig1–4 modules formed also in
FIG. 5. Model for cell-cell adhesion by cis-assisted trans-bind-
ing of axonin-1. An axonin-1-mediated cell-cell contact is initiated by
the installment of a linear string of axonin-1 molecules that are alter-
nately provided by the two apposed membranes and trans-bound by a
large edge-to-face contact between adjacent Ig1–4 modules. By cis-
contacts, the membrane-proximal Fn domains promote the association
of linear strings into a two-dimensional array and thus enlarge and
strengthen the cell-cell contact. For better clarity, axonin-1 molecules of
the two apposed membranes are shown in distinct colors. To allow
better insight into the organization of axonin-1 molecules interacting in
a cis-assisted trans-interaction, some of the axonin-1 molecules in the
front were trimmed down to the three membrane-proximal Fn domains.
Membrane-bound monomeric axonin-1 is thought to be folded in a
horseshoe-like form. It is possible that the cis-site in the Fn region is
masked in monomeric axonin-1 by the back-folded Ig1–4 module; and
therefore, an associated monomeric axonin-1 with trans-bound axo-
nin-1 is excluded.
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the absence of the Fn moiety. Thus, the cis-binding among Fn
regions of axonin-1 rather plays a role after the trans-binding
by the Ig1–4 modules has been installed. It serves the expan-
sion and enhancement of the cell-cell contact area initiated by
the formation of linear strings of trans-bound axonin-1. After
the first cis-contact of Fn domains of axonin-1 of two linear
strings has become established, adjacent axonin-1 molecules of
the one string would preferably become engaged in cis-contacts
with adjacent axonin-1 molecules of the other string, resulting
in the lateral alignment of the strings. Weak affinity between
Fn domains provided, imperfect alignments could be improved,
as single contacts could be broken and new ones established
repeatedly during an ongoing optimization period until a par-
allel arrangement of multiple strings is reached. A further
optimization of the package of trans-bound axonin-1 molecules
would be realized by the exclusion of monomeric axonin-1 mol-
ecules from the contact area.
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